Skip to main content

Table 5 Toxicity profiles for the initial gefitinib and 2nd EGFR-TKI treatments. Adverse events were evaluated according to Common Terminology Criteria for Adverse Events of the National Cancer Institute (version 3.0).

From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Case Initial gefitinib 2nd EGFR-TKI
1 - Rash G2
2 Rash G2 -
3 - -
4 Rash G2, Liver G1, Diarrhea G2 Rash G1, Diarrhea G1
5 Rash G1 Rash G2
6 Diarrhea G2, Taste alteration G2 Rash G1, Diarrhea G1
7 Rash G2, Liver G3 Rash G2, Liver G3
8 Rash G2 Liver G2
9 Rash G1, Nail G1, Nausea G1 Rash G1
10 Liver G1 -
11 - Rash G1, Diarrhea G1
  1. G, grade; Liver, serum glutamic pyruvic transminase, serum glutamic oxaloacetic transaminase and γ-glutamyltranspeptidase.